The Complement 3 Glomerulopathy (C3G) market is poised for significant growth, driven by a deeper understanding of complement pathway dysregulation, improved diagnostic capabilities, and the introduction of novel targeted therapies such as Factor B inhibitors, C3 inhibitors, MASP-3 inhibitors, and RNA interference-based treatments. The emergence of innovative therapies, including FABHALTA (iptacopan), EMPAVELI/ASPAVELI (pegcetacoplan), KP104, Zaltenibart, and ARO-C3, is expected to redefine the treatment paradigm and unlock substantial commercial opportunities across the 7MM.
DelveInsight’s latest report, “Complement 3 Glomerulopathy (C3G) – Market Insights, Epidemiology and Market Forecast – 2036,” provides a comprehensive analysis of evolving treatment landscapes, epidemiology trends, and market growth dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover comprehensive insights into the C3G market outlook: https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Complement 3 Glomerulopathy (C3G) Market Summary
The Complement 3 Glomerulopathy market is expected to witness robust expansion through 2036, reaching approximately USD 1 billion, driven by a strong pipeline of targeted therapies and increasing disease awareness.
- The C3G market is projected to grow at a CAGR of nearly 28% during 2026–2036.
- The United States dominates the market, contributing nearly 70% of the total 7MM market share.
- In 2025, the diagnosed prevalent population of C3G in the 7MM was approximately 6,000 cases, expected to rise steadily due to improved diagnostics.
- Key companies, including Novartis, Apellis Pharmaceuticals, Sobi, Kira Pharmaceuticals, Novo Nordisk/Omeros Corporation, and Arrowhead Pharmaceuticals, are actively developing innovative therapies.
- Emerging therapies such as KP104, Zaltenibart, and ARO-C3 are expected to significantly enhance treatment outcomes and expand market potential.
Explore detailed market size forecasts and growth trends: https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Key Factors Driving the Growth of the C3G Market
Advancements in Complement Biology
Recent breakthroughs in understanding the alternative complement pathway have enabled the development of highly targeted therapies. These therapies directly address the underlying disease mechanism, improving efficacy compared to traditional immunosuppressive treatments.
Improved Diagnostic Capabilities
The growing adoption of genetic testing, complement assays, and advanced renal biopsy techniques has significantly improved early diagnosis rates. Multidisciplinary approaches are enhancing diagnostic accuracy, enabling timely intervention.
Rising Disease Awareness and Reporting
Increased retrospective studies and improved data collection in nephrology centers indicate that C3G may be more prevalent than previously estimated. This has expanded the addressable patient population.
High Disease Burden and Unmet Needs
C3G is associated with a severe disease course, with 30–50% of patients progressing to end-stage kidney disease within 10 years. The lack of historically approved therapies has created strong demand for innovative solutions.
Launch of Novel Targeted Therapies
The approval of FABHALTA (iptacopan) and EMPAVELI/ASPAVELI (pegcetacoplan) marks a transformative phase in C3G treatment. Upcoming therapies with novel mechanisms are expected to further accelerate market growth.
Analyst Perspective
DelveInsight analysts highlight that complement inhibition strategies are emerging as a cornerstone in C3G treatment. The transition from non-specific immunosuppression to precision-targeted therapies is expected to significantly improve patient outcomes.
Despite recent approvals, there remains substantial opportunity for therapies offering improved safety profiles, long-term efficacy, and broader patient applicability, including pediatric and transplant populations.
Complement 3 Glomerulopathy (C3G) Market Analysis
Currently, the treatment of C3G relies heavily on off-label therapies, including corticosteroids, immunosuppressants, and RAAS inhibitors. These approaches primarily focus on slowing disease progression rather than addressing the root cause.
The approval of targeted complement inhibitors has reshaped the treatment paradigm:
- FABHALTA (iptacopan) – First approved Factor B inhibitor targeting the alternative pathway.
- EMPAVELI/ASPAVELI (pegcetacoplan) – A C3 inhibitor offering upstream complement blockade.
Additional off-label therapies include monoclonal antibodies such as eculizumab and rituximab, which target the terminal complement pathway.
However, safety concerns such as the risk of life-threatening infections due to complement inhibition remain a key challenge, necessitating vaccination protocols prior to treatment.
Complement 3 Glomerulopathy (C3G) Competitive Landscape
The competitive landscape is rapidly evolving, with both established pharmaceutical companies and emerging biotech firms investing heavily in complement-targeted therapies.
Key Marketed Therapies
FABHALTA (Iptacopan) – Novartis
An oral Factor B inhibitor that directly blocks the alternative complement pathway. It received FDA approval in 2025, marking a significant milestone in C3G treatment.
EMPAVELI/ASPAVELI (Pegcetacoplan) – Apellis Pharmaceuticals and Sobi
A C3 inhibitor that offers broader complement blockade. It has demonstrated strong clinical efficacy and gained approvals across major markets.
Emerging Complement 3 Glomerulopathy (C3G) Pipeline Therapies
- KP104 (Kira Pharmaceuticals) – Dual inhibitor targeting C5 and Factor H
- Zaltenibart (Omeros/Novo Nordisk) – MASP-3 inhibitor
- ARO-C3 (Arrowhead Pharmaceuticals) – RNA interference therapy targeting C3
These therapies are expected to introduce differentiated mechanisms, improving treatment outcomes and expanding therapeutic options.
Access full pipeline analysis and competitive benchmarking: https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Recent Developments in the Complement 3 Glomerulopathy (C3G) Market
- In January 2026, Sobi announced that the European Commission has approved ASPAVELI for the treatment of adult and adolescent patients aged 12 to 17 years with C3G or primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) in combination with a Renin-Angiotensin System (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
- In June 2025, Apellis Pharmaceuticals presented new data from the open-label period of the Phase III (VALIANT) study, investigating pegcetacoplan for C3G and primary IC-MPGN. The data were presented as part of a late-breaking session at the ERA Congress.
- July 2025 – FDA approved pegcetacoplan for patients aged 12 years and older.
- March 2025 – FDA approved iptacopan as the first targeted therapy for C3G.
These developments highlight rapid progress in clinical innovation and regulatory approvals.
What is Complement 3 Glomerulopathy (C3G)?
Complement 3 Glomerulopathy is a rare kidney disorder caused by dysregulation of the alternative complement pathway, leading to excessive C3 deposition in the glomeruli.
It includes two main subtypes:
- Dense Deposit Disease (DDD)
- C3 Glomerulonephritis (C3GN)
Patients typically present with proteinuria, hematuria, reduced kidney function, and edema. Diagnosis requires kidney biopsy along with immunofluorescence and electron microscopy.
Complement 3 Glomerulopathy (C3G) Epidemiology Insights
- In 2025, the total diagnosed prevalent population in the 7MM was around 6,000 cases.
- The US accounted for approximately 3,500 cases.
- Adults represented nearly 90% of cases in the US.
- The patient population is expected to grow steadily through 2036.
The report provides detailed segmentation based on:
- Total diagnosed prevalent population
- Type-specific cases (DDD vs C3GN)
- Age-specific distribution
- Treated patient population
Download free sample report now: https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Complement 3 Glomerulopathy (C3G) Market Outlook
The treatment of C3G has largely depended on off-label use of medications, highlighting the lack of approved, disease-specific therapies. Current management primarily includes immunosuppressants, corticosteroids, RAAS inhibitors, and supportive treatments such as calcineurin inhibitors and antibodies.
Additional off-label approaches involve monoclonal antibodies like eculizumab and rituximab, which target the terminal complement pathway by inhibiting C5. These therapies can help improve kidney function and reduce proteinuria, particularly in patients showing elevated C5b-9 levels, a common feature in C3G.
A major shift in the treatment landscape occurred in 2025 with the FDA approval of Iptacopan, the first targeted therapy for C3G, followed by Pegcetacoplan, expanding treatment options for patients aged 12 and above.
The United States dominates the C3G market, accounting for nearly 70% of the total market across the 7MM. Meanwhile, the pipeline remains promising, with key therapies such as KP104, Zaltenibart (OMS906), and ARO-C3 under development by leading companies, expected to significantly drive future market growth and innovation.
Complement 3 Glomerulopathy (C3G) Unmet Needs
Despite advancements, several challenges persist:
- Lack of early diagnostic biomarkers
- Risk of misdiagnosis with similar glomerular diseases
- Limited long-term efficacy data
- High disease burden and progression rates
Addressing these gaps will be critical for improving patient outcomes and driving market growth.
Request for free sample report: https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Complement 3 Glomerulopathy (C3G) Market Access and Pricing Insights
The high cost of complement inhibitors presents challenges for reimbursement and accessibility. For instance:
- EMPAVELI annual treatment cost exceeds USD 500,000
Payers are exploring innovative reimbursement models to improve patient access while managing healthcare costs.
Conclusion
The Complement 3 Glomerulopathy market is entering a transformative phase marked by scientific innovation, regulatory breakthroughs, and increasing investment in targeted therapies. With a projected market size of USD 1 billion by 2036, the space offers significant opportunities for stakeholders across the pharmaceutical and healthcare ecosystem.
